Fotemustine

Summary

Fotemustine (CHEMBL549386) is a phase-3 clinical-stage small molecule (ATC L01AD05); indicated across 5 conditions including neoplasm and cutaneous melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01AD05
• Indications: 5 conditions
• Clinical trials: 8
• Chemistry: 315.69 Da · C9H19ClN3O5P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL549386
Name	Fotemustine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	104799
ChEBI	CHEBI:131852
ATC	L01AD05
Molecular formula	C9H19ClN3O5P
Molecular weight	315.69
InChIKey	YAKWPXVTIGTRJH-UHFFFAOYSA-N

SMILES: CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC

IUPAC name: 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea

ChEBI definition: A member of the class of N-nitrosoureas that is ethyl diethylphosphonate in the hydrogen at position 1 of the ethyl group attached to the phosphorus has been replaced by a [(2-chloroethyl)(nitroso)carbamoyl]amino group.

Also known as: Fotemustina, Fotemustine, Muphoran, Mustophorane, S-10036, S10036, FOTEMUSTINE, SID174007311

Patent coverage: 11,339 distinct patent families (49,819 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
melanoma	3	MONDO:0005105	EFO:0000756
ocular melanoma	3	MONDO:0006325	EFO:1000403
glioblastoma	2	MONDO:0018177	EFO:0000519

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00110123	PHASE3	TERMINATED	Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
NCT01359956	PHASE3	COMPLETED	Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
NCT02460068	PHASE3	UNKNOWN	A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
NCT00560118	PHASE2	TERMINATED	Fotemustine in Treating Patients With Metastatic Melanoma
NCT01069627	PHASE2	COMPLETED	A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
NCT01474239	PHASE2	COMPLETED	A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
NCT01654692	PHASE2	COMPLETED	A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
NCT01983124	PHASE2	COMPLETED	Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).